NeuroSigma, which develops electrical devices used to treat drug-resistant epilepsy and depression, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering. The company is in pivotal trials to have its bioelectronic products approved in the US, and has received marketing approval in Australia, Canada and the EU.
Recent epilepsy IPOs include biotechs Marinus Pharmaceuticals (MRNS) and Sage Therapeutics (SAGE).
The Los Angeles, CA-based company, which was founded in 2008 and booked $52,000 in sales for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol NSIG. NeuroSigma initially filed confidentially on November 27, 2013. Jefferies is the sole bookrunner on the deal. No pricing terms were disclosed.
